Literature DB >> 10601242

Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25. Identification of the minimal essential C-terminal residues.

G A O'Sullivan1, N Mohammed, P G Foran, G W Lawrence, J Oliver Dolly.   

Abstract

Botulinum neurotoxin (BoNT) types A and B selectively block exocytosis by cleavage of SNAP-25 and synaptobrevin, respectively; in humans, many months are required for full recovery from the resultant neuromuscular paralysis. To decipher the molecular basis for such prolonged poisoning, intoxication in adreno-chromaffin cells was monitored over 2 months. Exocytosis from BoNT/B-treated cells resumed after 56 days because of the appearance of intact synaptobrevin. However, inhibition continued in BoNT/A-treated cells, throughout the same interval, with a continued predominance of cleaved SNAP-25-(1-197) over the intact protein. When recovery from poisoning was attempted by transfection of the latter cells with the gene encoding full-length SNAP-25-(1-206), no restoration of exocytosis ensued even after 3 weeks. To ascertain if this failure was because of the persistence of the toxin's protease activity, the cells were transfected with BoNT/A-resistant SNAP-25 constructs; importantly, exocytosis was rescued. C-terminal truncation of the toxin-insensitive SNAP-25 revealed that residues 1-201, 1-202, 1-203 afforded a significant return of exocytosis, unlike shorter forms 1-197, -198, -199, or -200; accordingly, mutants M202A or L203A of full-length SNAP-25 rescued secretion. These findings give insights into the C-terminal functional domain of SNAP-25, demonstrate the longevity of BoNT/A protease, and provide the prospect of a therapy for botulism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10601242     DOI: 10.1074/jbc.274.52.36897

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  The abscisic acid-related SNARE homolog NtSyr1 contributes to secretion and growth: evidence from competition with its cytosolic domain.

Authors:  Danny Geelen; Barbara Leyman; Henri Batoko; Gian-Pietro Di Sansebastiano; Ian Moore; Michael R Blatt; Gian-Pietro Di Sansabastiano
Journal:  Plant Cell       Date:  2002-02       Impact factor: 11.277

Review 2.  The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.

Authors:  Sergio Pantano; Cesare Montecucco
Journal:  Cell Mol Life Sci       Date:  2013-06-11       Impact factor: 9.261

3.  Persistence of Botulinum neurotoxin inactivation of nerve function.

Authors:  Charles B Shoemaker; George A Oyler
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 4.  Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.

Authors:  Brenda A Wilson; Mengfei Ho
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

5.  Symptomatic treatment of botulism with a clinically approved small molecule.

Authors:  Edwin Vazquez-Cintron; James Machamer; Celinia Ondeck; Kathleen Pagarigan; Brittany Winner; Paige Bodner; Kyle Kelly; M Ross Pennington; Patrick McNutt
Journal:  JCI Insight       Date:  2020-01-30

6.  Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication.

Authors:  Yien Che Tsai; Archana Kotiya; Erkan Kiris; Mei Yang; Sina Bavari; Lino Tessarollo; George A Oyler; Allan M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-05       Impact factor: 11.205

7.  The core membrane fusion complex governs the probability of synaptic vesicle fusion but not transmitter release kinetics.

Authors:  Michael F A Finley; Sejal M Patel; Daniel V Madison; Richard H Scheller
Journal:  J Neurosci       Date:  2002-02-15       Impact factor: 6.167

8.  Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system.

Authors:  Yien Che Tsai; Rhyan Maditz; Chueh-ling Kuo; Paul S Fishman; Charles B Shoemaker; George A Oyler; Allan M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-07       Impact factor: 11.205

9.  Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A.

Authors:  Mengfei Ho; Cheong-Hian Goh; Michael C Brothers; Shihua Wang; Ryan L Young; Yuxiang Ou; Juliana Nga-Man Lui; Marinos Kalafatis; Xiuwan Lan; Abigail E Wolf; Chad M Rienstra; Brenda A Wilson
Journal:  Protein Sci       Date:  2012-03       Impact factor: 6.725

Review 10.  Drug Insight: biological effects of botulinum toxin A in the lower urinary tract.

Authors:  Michael B Chancellor; Clare J Fowler; Apostolos Apostolidis; William C de Groat; Christopher P Smith; George T Somogyi; K Roger Aoki
Journal:  Nat Clin Pract Urol       Date:  2008-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.